Skip to main content
Weight Management
resource center
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
Allergic Asthma
Atopic Dermatitis Care
Chronic Kidney Disease
COVID-19
Depression Care
Endometriosis
Eosinophilic Disease
Exocrine Pancreatic Insufficiency
Gynecologic Surgical Bleeding
HIV Management
HIV Prevention
Intraoperative Bleeding
Oral Health
Psoriasis Care
Pulmonary Arterial Hypertension
Ulcerative Colitis
Uncontrolled Asthma
Resources
AbbVie Partner Spotlight
Commentary
Disease State Directory
Eosinophilic Disorders Clinical Update
FDA Alerts
News
Pearls
Podcasts
Polls
Q&As
Quizzes
Slideshows
T2D: Don’t Sugar Coat It
Videos
Events & Education
Consultant360's Practical Updates in Primary Care
CME
Congress of Clinical Rheumatology - East
Publications
Advertising With Consultant360
Author Guidelines
Consultant Archive
Consultant Current Issue
Consultant Early View
Writing Clinic
Search
Login
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
Allergic Asthma
Atopic Dermatitis Care
Chronic Kidney Disease
COVID-19
Depression Care
Endometriosis
Eosinophilic Disease
Exocrine Pancreatic Insufficiency
Gynecologic Surgical Bleeding
HIV Management
HIV Prevention
Intraoperative Bleeding
Oral Health
Psoriasis Care
Pulmonary Arterial Hypertension
Ulcerative Colitis
Uncontrolled Asthma
Resources
AbbVie Partner Spotlight
Commentary
Disease State Directory
Eosinophilic Disorders Clinical Update
FDA Alerts
News
Pearls
Podcasts
Polls
Q&As
Quizzes
Slideshows
T2D: Don’t Sugar Coat It
Videos
Events & Education
Consultant360's Practical Updates in Primary Care
CME
Congress of Clinical Rheumatology - East
Publications
Advertising With Consultant360
Author Guidelines
Consultant Archive
Consultant Current Issue
Consultant Early View
Writing Clinic
Weight Management
Resource Center
News
News
Resources
FDA Alerts
Pearls of Wisdom
From the Journal
Insights
Commentary
Q&As
Interactive
Polls
FDA Alerts
Addiction
Addiction
FDA approves ADHD drug Vyvanse for binge-eating disorder
02/02/2015
The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.
02/02/2015
